Baird on Dyne Therapeutics (DYN): 'Positive on clinical progress and improved regulatory dynamic'
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $30.00 price target on Dyne Therapeutics (NASDAQ: DYN).The analyst comments "Positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
